GB201405784D0 - Novel methods, polypeptides and uses thereof - Google Patents

Novel methods, polypeptides and uses thereof

Info

Publication number
GB201405784D0
GB201405784D0 GBGB1405784.8A GB201405784A GB201405784D0 GB 201405784 D0 GB201405784 D0 GB 201405784D0 GB 201405784 A GB201405784 A GB 201405784A GB 201405784 D0 GB201405784 D0 GB 201405784D0
Authority
GB
United Kingdom
Prior art keywords
polypeptides
novel methods
novel
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1405784.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzymatica AB
Original Assignee
Enzymatica AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymatica AB filed Critical Enzymatica AB
Priority to GBGB1405784.8A priority Critical patent/GB201405784D0/en
Publication of GB201405784D0 publication Critical patent/GB201405784D0/en
Priority to DK15708564.8T priority patent/DK3099317T3/da
Priority to JP2016549436A priority patent/JP6718375B2/ja
Priority to US15/115,065 priority patent/US20160339087A1/en
Priority to CN201580017331.9A priority patent/CN106232810A/zh
Priority to RU2016135003A priority patent/RU2732378C2/ru
Priority to AU2015212554A priority patent/AU2015212554B2/en
Priority to PCT/GB2015/050212 priority patent/WO2015114343A1/en
Priority to EP15708564.8A priority patent/EP3099317B1/en
Priority to EP21180866.2A priority patent/EP3932420A1/en
Priority to BR112016017478A priority patent/BR112016017478A2/pt
Priority to PT157085648T priority patent/PT3099317T/pt
Priority to MX2016009850A priority patent/MX384716B/es
Priority to ES15708564T priority patent/ES2890555T3/es
Priority to PL15708564T priority patent/PL3099317T3/pl
Priority to KR1020167023814A priority patent/KR20160108560A/ko
Priority to AU2015242380A priority patent/AU2015242380A1/en
Priority to EP15719816.9A priority patent/EP3125926A1/en
Priority to JP2016559234A priority patent/JP2017511133A/ja
Priority to BR112016022584A priority patent/BR112016022584A2/pt
Priority to RU2016142580A priority patent/RU2016142580A/ru
Priority to CN201580018134.9A priority patent/CN106257988A/zh
Priority to PCT/GB2015/051006 priority patent/WO2015150799A1/en
Priority to US15/300,567 priority patent/US20170107503A1/en
Priority to US16/395,962 priority patent/US20190343932A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Birds (AREA)
GBGB1405784.8A 2014-01-29 2014-03-31 Novel methods, polypeptides and uses thereof Ceased GB201405784D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB1405784.8A GB201405784D0 (en) 2014-03-31 2014-03-31 Novel methods, polypeptides and uses thereof
KR1020167023814A KR20160108560A (ko) 2014-01-29 2015-01-29 신규 치료
MX2016009850A MX384716B (es) 2014-01-29 2015-01-29 Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia.
PL15708564T PL3099317T3 (pl) 2014-01-29 2015-01-29 Trypsyna z dorsza do zastosowania do leczenia zakażeń drobnoustrojowych u osobnika z niedoborem odporności
US15/115,065 US20160339087A1 (en) 2014-01-29 2015-01-29 Novel treatments
CN201580017331.9A CN106232810A (zh) 2014-01-29 2015-01-29 新的治疗
RU2016135003A RU2732378C2 (ru) 2014-01-29 2015-01-29 Новые виды лечения
AU2015212554A AU2015212554B2 (en) 2014-01-29 2015-01-29 Novel treatments
PCT/GB2015/050212 WO2015114343A1 (en) 2014-01-29 2015-01-29 Novel treatments
EP15708564.8A EP3099317B1 (en) 2014-01-29 2015-01-29 Cod trypsin for use in the treatment of microbial infections in a subject with immunodeficiency
EP21180866.2A EP3932420A1 (en) 2014-01-29 2015-01-29 Novel treatments
BR112016017478A BR112016017478A2 (pt) 2014-01-29 2015-01-29 novos tratamentos
PT157085648T PT3099317T (pt) 2014-01-29 2015-01-29 Tripsina de bacalhau para utilização no tratamento de infeções microbianas num indivíduo com imunodeficiência
DK15708564.8T DK3099317T3 (en) 2014-01-29 2015-01-29 Cod trypsin for use in the treatment of microbial infections in a subject with immunodeficiency
ES15708564T ES2890555T3 (es) 2014-01-29 2015-01-29 Tripsina de bacalao para uso en el tratamiento de infecciones microbianas en un sujeto con inmunodeficiencia
JP2016549436A JP6718375B2 (ja) 2014-01-29 2015-01-29 新規治療法
US15/300,567 US20170107503A1 (en) 2014-03-31 2015-03-31 Novel methods, polypeptides and uses thereof
AU2015242380A AU2015242380A1 (en) 2014-03-31 2015-03-31 Novel methods, polypeptides and uses thereof
EP15719816.9A EP3125926A1 (en) 2014-03-31 2015-03-31 Novel methods, polypeptides and uses thereof
JP2016559234A JP2017511133A (ja) 2014-03-31 2015-03-31 新規の方法、ポリペプチド、及びその使用
BR112016022584A BR112016022584A2 (pt) 2014-03-31 2015-03-31 métodos inovadores, polipeptídeos e usos dos mesmos
RU2016142580A RU2016142580A (ru) 2014-03-31 2015-03-31 Новые способы, полипептиды и их применение
CN201580018134.9A CN106257988A (zh) 2014-03-31 2015-03-31 新颖方法、多肽以及其用途
PCT/GB2015/051006 WO2015150799A1 (en) 2014-03-31 2015-03-31 Novel methods, polypeptides and uses thereof
US16/395,962 US20190343932A1 (en) 2014-01-29 2019-04-26 Novel treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1405784.8A GB201405784D0 (en) 2014-03-31 2014-03-31 Novel methods, polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
GB201405784D0 true GB201405784D0 (en) 2014-05-14

Family

ID=50737758

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1405784.8A Ceased GB201405784D0 (en) 2014-01-29 2014-03-31 Novel methods, polypeptides and uses thereof

Country Status (9)

Country Link
US (1) US20170107503A1 (enExample)
EP (1) EP3125926A1 (enExample)
JP (1) JP2017511133A (enExample)
CN (1) CN106257988A (enExample)
AU (1) AU2015242380A1 (enExample)
BR (1) BR112016022584A2 (enExample)
GB (1) GB201405784D0 (enExample)
RU (1) RU2016142580A (enExample)
WO (1) WO2015150799A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120866A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
CN110621777A (zh) * 2017-03-15 2019-12-27 杜邦营养生物科学有限公司 胰蛋白酶样丝氨酸蛋白酶及其用途
GB201800274D0 (en) 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201801982D0 (en) 2018-02-07 2018-03-28 Enzymatica Ab Novel treatments
WO2020229145A1 (en) * 2019-05-13 2020-11-19 Bioseutica B.V. Purified fish proteases with high specific activities and its process of production
KR20220157997A (ko) 2020-03-23 2022-11-29 케레시스 아게 항균 용액 및 이것을 감염의 치료 또는 예방에 사용하는 방법
EP4344749A3 (en) * 2020-05-13 2024-06-26 ZYMIQ Technology AB Protease formulation for treatment of microbial infections
CN115778864B (zh) * 2022-12-12 2024-04-19 广州市美夫兰化妆品有限公司 一种祛斑净白抗皱冻干粉

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
PT1202743E (pt) 1999-06-18 2005-02-28 Jon Bragi Bjarnason Composicoes farmaceuticas e cosmeticas compreendendo serina-proteases de bacalhau e sua utilizacao farmaceutica e cosmetica
WO2012104099A1 (en) * 2011-02-04 2012-08-09 Glucometrix Ag Process for the production of recombinant trypsin
JP6718375B2 (ja) * 2014-01-29 2020-07-08 エンツィマティカ アクティエ ボラーグ 新規治療法

Also Published As

Publication number Publication date
RU2016142580A3 (enExample) 2018-11-28
CN106257988A (zh) 2016-12-28
US20170107503A1 (en) 2017-04-20
RU2016142580A (ru) 2018-05-07
WO2015150799A1 (en) 2015-10-08
EP3125926A1 (en) 2017-02-08
AU2015242380A1 (en) 2016-11-10
BR112016022584A2 (pt) 2017-10-10
JP2017511133A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
IL320713A (en) Antibodies, uses and methods
IL275307B (en) Syntac polypeptides and their uses
IL247407B (en) Antibodies against egfrviii and their uses
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
SG10201912019WA (en) Novel specific-binding polypeptides and uses thereof
GB201405784D0 (en) Novel methods, polypeptides and uses thereof
SG11201704473WA (en) New methods and uses
ZA201701348B (en) New polypeptides
GB201408673D0 (en) Medicaments,uses and methods
IL257434A (en) Mrka polypeptides, antibodies, and uses thereof
GB201410031D0 (en) Polypeptides and uses thereof
IL251289B (en) New peptide derivatives and their use
GB201408091D0 (en) Methods and uses
IL249073B (en) Cytin-glucan complex, its preparation and uses
SG11201610918RA (en) Peptides and uses thereof
IL246533A0 (en) new proteins
GB201419237D0 (en) Novel polypeptides
GB201410265D0 (en) Novel polypeptides
GB201403024D0 (en) Polypeptides
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)